The Effect of Hemodialysis on Hearing Using Pure-Tone Audiometry and Distortion-Product Otoacoustic Emissions

ORL ◽  
1998 ◽  
Vol 60 (6) ◽  
pp. 306-313 ◽  
Author(s):  
Orhan Ozturan ◽  
Samuel Lam
Keyword(s):  
Otoacoustic Emissions ◽  
Pure Tone ◽  
Pure Tone Audiometry ◽  
Distortion Product Otoacoustic Emissions ◽  
Distortion Product

Comparison of distortion product otoacoustic emissions and pure tone audiometry in occupational screening for auditory deficit due to noise exposure

2015 ◽  
Vol 129 (12) ◽  
pp. 1174-1181 ◽  
Author(s):  
N Wooles ◽  
M Mulheran ◽  
P Bray ◽  
M Brewster ◽  
A R Banerjee
Keyword(s):  
Otoacoustic Emissions ◽  
Pure Tone ◽  
Noise Exposure ◽  
Outer Hair Cell ◽  
Cell Function ◽  
Pure Tone Audiometry ◽  
Otoacoustic Emission ◽  
Distortion Product Otoacoustic Emissions ◽  
Distortion Product Otoacoustic Emission ◽  
Distortion Product

AbstractObjective:To examine whether distortion product otoacoustic emissions can serve as a replacement for pure tone audiometry in longitudinal screening for occupational noise exposure related auditory deficit.Methods:A retrospective review was conducted of pure tone audiometry and distortion product otoacoustic emission data obtained sequentially during mandatory screening of brickyard workers (n = 16). Individual pure tone audiometry thresholds were compared with distortion product otoacoustic emission amplitudes, and a correlation of these measurements was conducted.Results:Pure tone audiometry threshold elevation was identified in 13 out of 16 workers. When distortion product otoacoustic emission amplitudes were compared with pure tone audiometry thresholds at matched frequencies, no evidence of a robust relationship was apparent. Seven out of 16 workers had substantial distortion product otoacoustic emissions with elevated pure tone audiometry thresholds.Conclusion:No clinically relevant predictive relationship between distortion product otoacoustic emission amplitude and pure tone audiometry threshold was apparent. These results do not support the replacement of pure tone audiometry with distortion product otoacoustic emissions in screening. Distortion product otoacoustic emissions at frequencies associated with elevated pure tone audiometry thresholds are evidence of intact outer hair cell function, suggesting that sites distinct from these contribute to auditory deficit following ototrauma.

ROLE OF AUDIOLOGICAL SCREENING (PURE TONE AUDIOMETRY AND DISTORTION PRODUCT OTOACOUSTIC EMISSIONS) IN PATIENTS UNDERGOING CONCURRENT CHEMORADIATION FOR HEAD AND NECK CANCERS

2016 ◽  
Vol 1 (1) ◽  
Author(s):  
Anisha Kocchar ◽  
Rohit Sharma ◽  
Piyush Kumar ◽  
Vineet Sharma ◽  
Kumar Shubhanshu
Keyword(s):  
Head And Neck ◽  
Otoacoustic Emissions ◽  
Pure Tone ◽  
Pure Tone Audiometry ◽  
Head And Neck Cancers ◽  
Concurrent Chemoradiation ◽  
Distortion Product Otoacoustic Emissions ◽  
Distortion Product ◽  
Pre Treatment

<bold>Introduction:</bold> Chemoradiation is an important component in the management of Head and Neck Cancers, which has hearing loss as a major adverse effect. This is due to the inclusion of ear structures in the radiation field and Cisplatin, an anti-neoplastic drug which can cause ototoxicity. The role of audiological screening in the form of Pure Tone Audiometry & Distortion Product Otoacoustic Emissions is hereby studied in these patients. <bold>Material and Methods:</bold> The present study was undertaken to highlight the effects of concurrent chemoradiation on the audiological profile of Head and Neck Cancer patients. The patients underwent pre-treatment and post treatment Pure Tone Audiometry and Distortion Product Otoacoustic Emission. The results were statistically analysed. <bold>Results:</bold> 36 patients who underwent concurrent chemoradiation for Head and Neck Cancers were enrolled. Post treatment PTA values were significantly different from Pre-treatment values especially at 500Hz. DPOAEs also indicated significant changes in cochleotoxicity grading after concurrent chemoradiation. <bold>Conclusion:</bold> Concurrent Chemoradiation exerts a significant effect on hearing status of the patients. Simple screening tests like DPOAE can detect cochlear damage prior to detection with Pure Tone Audiometry. Addition of these tests is recommended as routine screening during Concurrent Chemoradiation.

Evaluation of Efferent Auditory System and Hearing Quality in Parkinson's Disease: Is the Difficulty in Speech Understanding in Complex Listening Conditions Related to Neural Degeneration or Aging?

2020 ◽  
pp. 1-9
Author(s):  
Nuriye Yıldırım Gökay ◽  
Bülent Gündüz ◽  
Fatih Söke ◽  
Recep Karamert
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Auditory System ◽  
Otoacoustic Emissions ◽  
Pure Tone ◽  
Pure Tone Audiometry ◽  
Auditory Pathway ◽  
Normal Hearing ◽  
System Function ◽  
Distortion Product

Purpose The effects of neurological diseases on the auditory system have been a notable issue for investigators because the auditory pathway is closely associated with neural systems. The purposes of this study are to evaluate the efferent auditory system function and hearing quality in Parkinson's disease (PD) and to compare the findings with age-matched individuals without PD to present a perspective on aging. Method The study included 35 individuals with PD (mean age of 48.50 ± 8.00 years) and 35 normal-hearing peers (mean age of 49 ± 10 years). The following tests were administered for all participants: the first section of the Speech, Spatial and Qualities of Hearing Scale; pure-tone audiometry, speech audiometry, tympanometry, and acoustic reflexes; and distortion product otoacoustic emissions (DPOAEs) and contralateral suppression of DPOAEs. SPSS Version 25 was used for statistical analyses, and values of p < .05 were considered statistically significant. Results There were no statistically significant differences in the pure-tone audiometry thresholds and DPOAE responses between the individuals with PD and their normal-hearing peers ( p = .732). However, statistically significant differences were found between the groups in suppression levels of DPOAEs and hearing quality ( p < .05). In addition, a statistically significant and positive correlation was found between the amount of suppression at some frequencies and the Speech, Spatial and Qualities of Hearing Scale scores. Conclusions This study indicates that medial olivocochlear efferent system function and the hearing quality of individuals with PD were affected adversely due to the results of PD pathophysiology on the hearing system. For optimal intervention and follow-up, tasks related to hearing quality in daily life can also be added to therapies for PD.

scholarly journals Cochlear function in patients with chronic kidney disease

2013 ◽  
Vol 60 (1) ◽  
Author(s):  
Samantha Marlanie Govender ◽  
Cyril Devdas Govender ◽  
Glenda Matthews
Keyword(s):  
Chronic Kidney Disease ◽  
Hearing Loss ◽  
Kidney Disease ◽  
Otoacoustic Emissions ◽  
Pure Tone ◽  
Pure Tone Audiometry ◽  
Drug Intake ◽  
Cochlear Function ◽  
Distortion Product ◽  
Cochlear Dysfunction

Objective: To evaluate cochlear functioning in patients (18 - 45 years old) with varying stages of chronic kidney disease (CKD). Using purposive sampling, 50 participants, 10 in each of the 5 stages of CKD, were selected and underwent pure tone audiometric testing and distortion product otoacoustic emissions (DPOAEs).Results: Significant differences (p<0.05) were found between pure tone audiometry and DPOAEs in detecting early cochlear dysfunction in the high-frequency range in stages 3 (6 000/5 000 Hz; p=0.00), 4 (6 000/5 000 Hz; p<0.03) and 5 (4 000/3 333 Hz; p<0.01, 8 000/6 667 Hz:p<0.05) with DPOAEs being more sensitive in identifying early cochlear dysfunction. Patients in stages 1 and 2 presented with normal puretone thresholds and DPOAEs, suggesting that cochlear functioning in these patients was normal. Early cochlear dysfunction, thereby indicating a subclinical hearing loss, was identified in stages 3, 4 and 5 by DPOAE testing. In addition, blood test results, drug intake and concomitant conditions were recorded and analysed which suggested a relationship between reduced cochlear functioning and increased electrolyte levels, treatment regimens and concomitant conditions.Conclusion: Participants in the later stages of CKD presented with early cochlear dysfunction, presenting with subclinical hearing loss. It was postulated that this subclinical hearing loss resulted from a combination of electrolytic, urea and creatinine imbalances, together with concomitant medical conditions and ototoxic drug intake. It was concluded that audiological monitoring be included in the management of patients with CKD and that DPOAEs be introduced as part of the test battery to monitor cochlear function in patients with varying degrees of CKD.

scholarly journals Hubungan ototoksisitas dan kemoterapi neoadjuvan pada karsinoma nasofaring berdasarkan ASHA, CTCAE, dan DPOAE

2018 ◽  
Vol 47 (2) ◽  
pp. 102
Author(s):  
Meyrna Heryaning Putri ◽  
Pudji Rahaju ◽  
Dyah Indrasworo
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Early Detection ◽  
Adverse Events ◽  
Otoacoustic Emissions ◽  
Pure Tone ◽  
Distortion Product Otoacoustic Emissions ◽  
Hearing Level ◽  
Type Iii ◽  
Distortion Product ◽  
Significant Difference

Latar belakang: Kemoterapi neoadjuvan adalah induksi kemoterapi sebelum radioterapi dengan regimen cisplatin dan 5-Fluorouracil. Kemoterapi cisplatin bersifat ototoksik pada pendengaran sensorineural bilateral progresif dan bersifat irreversible. Kriteria dari American Speech-Language Hearing Association (ASHA) dan Common Terminology Criteria for Adverse Events (CTCAE) merupakan kriteria untuk mengidentifikasi ototoksisitas dengan menggunakan audiometri, selain pemeriksaan Distortion Product Otoacoustic Emissions (DPOAE). Tujuan: Mengidentifikasi hubungan ototoksisitas dengan kemoterapi neoadjuvan pada penderita karsinoma nasofaring (KNF) WHO tipe III menggunakan ASHA, CTCAE, serta DPOAE. Metode: Studi ini adalah penelitian observasional dengan desain cohort. Kriteria inklusi penelitian yaitu penderita baru KNF WHO tipe III, yang mendapatkan kemoterapi regimen standar dan berusia <60 tahun. Kriteria pemeriksaan DPOAE adalah penderita dengan ambang dengar ≤40 dB. Percontoh dilakukan pemeriksaan timpanometri, audiometri, dan DPOAE. Hasil: Terdapat 9 sampel percontoh penelitian. Uji repeated-ANOVA menunjukkan tidak ditemukan perbedaan bermakna pada tiga hasil pengukuran audiometri antara pascakemoterapi pertama, kedua, dan ketiga (p>0,05). Deteksi awal ototoksisitas menggunakan kriteria ASHA menunjukkan sensitivitas sebesar 67% dan dan CTCAE 44%, dibandingkan baku emas menggunakan DPOAE. Kesimpulan: Ototoksisitas cisplatin ditemukan sejak kemoterapi pertama dengan menggunakan pemeriksaan DPOAE walaupun tidak bermakna secara statistik. Kemampuan DPOAE untuk mendeteksi awal ototoksisitas lebih baik dibandingkan kriteria ASHA dan CTCAE yang menggunakan audiometri nada murni.Kata kunci: Karsinoma nasofaring, ototoksisitas sisplatin, DPOAE, CTCAE, ASHA ABSTRACT Introduction: Neoadjuvant chemotherapy is induction chemotherapy before radiotherapy with cisplatin and 5-Fluorouracyl regiment. Chemotherapy cisplatin is ototoxic, leads to frequently progresive and irreversible bilateral sensorineural hearing loss. American Speech-Language Hearing Association (ASHA) and Common Terminology Criteria for Adverse Events (CTCAE) are the criteria to determine ototoxicity with audiometry, beside Distortion Product Otoacoustic Emissions (DPOAE). Purpose: To identify the relationship between ototoxicity with neoadjuvant chemotherapy in patients NPC WHO type III using ASHA, CTCAE, and DPOAE. Method: This observational study approach with cohort design. Inclusion criteria: new patients NPC WHO type III who consented to undergo standard regiment chemotherapy, and age <60 year-old. For DPOAE examination: hearing level ≤40 dB. Exclucion criteria: NPC WHO type III patients who underwent chemotherapy with unconventional standard regiment. Examinations for hearing function conducted with tympanometry, pure tone audiometry, and Distortion Product Otoacoustic Emissions (DPOAE). Result: There were 9 sample in this study. The result of Repeated-ANOVA test showed no significant difference in three audiometry measurements among three series of chemotherapies. Early detection of ototoxicity using ASHA and CTCAE criterias showed sensitivity of 67% and 44% (compared with DPOAE as a gold standard). Conclusion: Cisplatin ototoxicity had occured since the first chemotherapy and detected with DPOAE, but statistically was not significantly related. Early detection of cisplatin ototoxicity with DPOAE was much better than with criteria American Speech-Language Hearing Association (ASHA) and Common Terminology Criteria for Adverse Events (CTCAE), which used pure tone audiometry.Keywords: Nasopharyngeal carcinoma, cisplatin ototoxicity, DPOAE, CTCAE, ASHA

A longitudinal study of changes in distortion-product otoacoustic emissions and pure-tone thresholds in an industrial setting

2013 ◽  
Vol 271 (10) ◽  
pp. 2649-2660
Author(s):  
Antonis Moukos ◽  
Dimitrios G. Balatsouras ◽  
Thomas Nikolopoulos ◽  
Pavlos Maragoudakis ◽  
Evangelos I. Yiotakis ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Otoacoustic Emissions ◽  
Pure Tone ◽  
Distortion Product Otoacoustic Emissions ◽  
Distortion Product ◽  
Industrial Setting

scholarly journals Relationship between Distortion Product Otoacoustic Emissions and Pure Tone Thresholds in Normal and Hearing-impaired Ears.

1997 ◽  
Vol 100 (4) ◽  
pp. 436-443 ◽  
Author(s):  
Eiji Chida ◽  
Nobukiyo Satoh ◽  
Mitsugu Kawanami ◽  
Masaaki Kashiwamura ◽  
Tohru Sakamoto ◽  
...  
Keyword(s):  
Otoacoustic Emissions ◽  
Pure Tone ◽  
Hearing Impaired ◽  
Distortion Product Otoacoustic Emissions ◽  
Distortion Product
Sign in / Sign up

Export Citation Format

Share Document